Auris Medical Provides Update on Intranasal Betahistine Programs
(WorldNews Switzerland)

Closes acquisition of Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Clinical trial applications for proof-of-concept studies with intranasal betahistine in acute vertigo and antipsychotic-induced weight gain submitted for recruitment start in first quarter 2019 Zug, Switzerland, January 15, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and CNS disorders, today provided an update on its intranasal betahistine development programs. In December 2018, the Company announced the acquisition of an Orphan Drug...